The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study
NCT ID: NCT07272265
Last Updated: 2025-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
300 participants
INTERVENTIONAL
2020-10-28
2025-11-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
NCT05886465
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
NCT07192185
HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama
NCT04627363
HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
NCT07045558
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
NCT06609863
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FOLFOX+TA
FOLOFOX-HAIC plus Atezolizumab and Bevacizumab
Atezolizumab & Bevacizumab
Atezolizumab 1200mg \& Bevacizumab 15mg/kg Q3W
FOLFOX-HAIC
hepatic artery infusion chemotherapy of oxaliplatin, leucovorin, and fluorouracil
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab & Bevacizumab
Atezolizumab 1200mg \& Bevacizumab 15mg/kg Q3W
FOLFOX-HAIC
hepatic artery infusion chemotherapy of oxaliplatin, leucovorin, and fluorouracil
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Initiating Atezo/Bev between 28 October 2020 and 31 June 2025
* Diagnosed with high-risk HCC as evidenced clinically or by radiology, histology or cytology before or at the initiation of Atezo/Bev plus HAIC. The evidence of being diagnosed as "high-risk" was based on the IMbrave 150, including any of the following:
* tumor invasion of the main trunk or contralateral branch of the portal vein (Vp4)
* bile duct invasion
* tumor occupancy of 50% or more of the liver
* At least one visit record after the initiation of Atezo/Bev plus HAIC
Exclusion Criteria
* Participating in interventional clinical studies before or at initiating Atezo/Bev plus HAIC
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shi Ming
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HAIC+TA Retrospective
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.